Pop-Busui R, Low PA, Waberski BH, et al
Since 2014, the combination of sofosbuvir/simeprevir/ribavirin and the new fixed-dose combinations ledipasvir/sofosbuvir and sofosbuvir/velpatasvir resulted in SVR rates of 92100% in trials enrolling patients infected with HCV GT1 34,35,36,37,38,39,40 and 85100% in other genotypes 40,41,42,43
Biomed and Angela Grace, MD of MIMS Indonesia for providing excellent medical writing and editorial assistance which was funded by embecta
Vendors that cannot document their supply chain where the bacteriostatic water comes from, who manufactured it, what testing was performed represent the same documentation gap as unverified marketplace sources
10.1006/frne.2001.0224 38 HajnalA.ZharikovA.PolstonJ